TEL AVIV, Israel--(BUSINESS WIRE)--InspireMD announced today receipt of orders for its MGuard Coronary stents. The orders came from key markets in Western Europe and Latin America, valued at more than $1.5M. MGuard™ Coronary Stent is designed to provide embolic shower protection during and post procedure. It is under investigation to treat patients with Coronary and SVG disease. In ongoing clinical trials conducted in Germany, interim results have shown a procedural success rate of 100% and no report of any major adverse cardiac events. To date, the MGuard ™ Coronary stent has shown safety in human coronary and vein graft indications.
